![](https://www.jhconline.com/wp-content/uploads/500x250px-2024-08-15T141916.113.jpg)
August 16, 2024- Thermo Fisher Scientific Inc. has received three R&D 100 Awards for innovations that aid researchers’ and scientists’ work in a variety of life science applications, including proteomics, bioproduction and small-molecule analysis. Notably, the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) won gold in the Market Disruptor special recognition category as one of the most significant advancements in mass spectrometry in 15 years.
This first-of-its-kind instrument, also recognized in the Analytical/Test Category for the R&D 100 Awards, combines fast throughput, high sensitivity, and deep proteome coverage, enabling researchers to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. The Orbitrap Astral MS delivers up to two times deeper proteome coverage and four times the throughput of current mass spectrometers. Further demonstrating the instrument’s impact, over 40 peer-reviewed and preprint publications have been published on the Orbitrap Astral MS since launch in 2023. The instrument is accelerating precision medicine by helping researchers reveal disease signatures earlier and develop new interventions for everything from cardiovascular disease to cancer.
Recognized in the Mechanical/Materials category, the Gibco™ CTS™ Detachable Dynabeads™ (CTS Detachable Dynabeads) platform also offers the first active release mechanism of its kind for clinical trial and commercial manufacturing use.